136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation - A podcast by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist

Send us a text Sickle cell disease affects thousands with severe daily pain. While FDA-approved gene therapies exist, their $2.2 million cost per treatment makes them largely inaccessible. In this episode of the Smart Biotech Scientist Podcast, David Brühlmann explores five key challenges facing the bioprocessing industry in making these therapies more accessible: Moving Away from Platform Technologies Traditional bioprocessing relies on platform technologies for antibody production. However,...